Serum S100B and Its Interplay With hs‐CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke
Open Access
- 1 September 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Abstract
Background: S100B (serum S100 calcium‐binding protein B) has been linked to blood–brain barrier disruption and neuroinflammation, but its prognostic value for ischemic stroke remains controversial. We aimed to examine baseline serum S100B and its interplay with high‐sensitivity C‐reactive protein and platelet count in association with clinical outcomes after ischemic stroke. Methods: Data were derived from a prospective multicenter cohort involving 3249 patients with acute ischemic stroke in 26 hospitals across China. Serum S100B concentrations were measured at baseline, and patients were followed up for 3 months after ischemic stroke. Study outcomes included death, major disability, and vascular events. Multivariable‐adjusted Cox proportional hazards regression models and logistic regression models were applied to estimate hazard ratios (HRs) or odds ratios (ORs) and their 95%CIs. Results: During the 3‐month follow‐up, 92 (2.8%) patients died. Higher baseline serum S100B levels were associated with an increased risk of death (quartile 4 versus quartile 1: adjusted HR, 2.09 [95% CI, 1.09–4.02]; P trend =0.028). Each SD increase in log‐transformed serum S100B was associated with a 38% greater risk of death. A spline regression model showed a linear relationship between serum S100B and death risk ( P linearity =0.006). Significant joint effects were observed between S100B and high‐sensitivity C‐reactive protein, and between S100B and platelet count, in association with death after ischemic stroke. The highest risk was observed among patients with elevations in all 3 biomarkers. Conclusions: Elevated serum S100B levels in the acute phase of ischemic stroke were independently associated with increased mortality risk. A single combined measure of S100B, high‐sensitivity C‐reactive protein, and platelet count may further improve risk stratification. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT01840072.Keywords
This publication has 36 references indexed in Scilit:
- Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet Neurology, 2024
- Biomarkers Predictive of Long-Term Outcome After Ischemic Stroke: A Meta-AnalysisWorld Neurosurgery, 2022
- Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020The Lancet Regional Health - Western Pacific, 2022
- The elevation of S100B and downregulation of circulating miR-602 in the sera of ischemic stroke (IS) patients: the emergence of novel diagnostic and prognostic markersNeurological Sciences, 2020
- S100B promotes microglia M1 polarization and migration to aggravate cerebral ischemiaInflammation Research, 2018
- Effects of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic StrokeJAMA, 2014
- S100B in neuropathologic states: The CRP of the brain?Journal of Neuroscience Research, 2007
- Evaluation of Serum S100B as a Surrogate Marker for Long-term Outcome and Infarct Volume in Acute Middle Cerebral Artery InfarctionArchives of Neurology, 2005
- S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional rolesThe International Journal of Biochemistry & Cell Biology, 2001
- Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic strokeJournal of the Neurological Sciences, 1997